Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.
Nakata
Tomoaki
T
Second Department of Internal Medicine (Cardiology), Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-0061, Japan. tnakata@sapmed.ac.jp
Wakabayashi
Takeru
T
Kyuma
Michifumi
M
Takahashi
Toru
T
Tsuchihashi
Kazufumi
K
Shimamoto
Kazuaki
K
D019797:3-Iodobenzylguanidine; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D015897:Comorbidity; D004338:Drug Combinations; D005260:Female; D006333:Heart Failure / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000401:mortality
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004338:Drug Combinations; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine